ARS Pharmaceuticals 대차 대조표 상태

재무 상태 기준 확인 6/6

ARS Pharmaceuticals 의 총 주주 지분은 $201.0M 이고 총 부채는 $0.0, 이는 부채 대 자기자본 비율을 0% 로 가져옵니다. 총자산과 총부채는 각각 $217.6M 및 $16.6M 입니다.

주요 정보

부채 비율

US$0

부채

이자 보상 비율	n/a
현금	US$204.82m
주식	US$200.98m
총 부채	US$16.62m
총 자산	US$217.60m

최근 재무 상태 업데이트

We're Interested To See How ARS Pharmaceuticals (NASDAQ:SPRY) Uses Its Cash Hoard To Grow

Sep 13

We're Not Very Worried About ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Rate

Mar 18

ARS Pharmaceuticals (NASDAQ:SPRY) Is In A Good Position To Deliver On Growth Plans

Nov 14

Here's Why We're Not Too Worried About ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Situation

May 12

Recent updates

ARS Pharmaceuticals: Demand Curve Is Key Unknown

Nov 20

We're Interested To See How ARS Pharmaceuticals (NASDAQ:SPRY) Uses Its Cash Hoard To Grow

Sep 13

ARS Pharmaceuticals (NASDAQ:SPRY) Is In A Good Position To Deliver On Growth Plans

Nov 14

Here's Why We're Not Too Worried About ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Situation

May 12

재무 상태 분석

단기부채: SPRY 의 단기 자산 ( $208.8M )이 단기 부채( $16.6M ).

장기 부채: SPRY 에는 장기 부채가 없습니다.

부채 대 자본 내역 및 분석

부채 수준: SPRY 부채가 없습니다.

부채 감소: SPRY 5년 전에 부채가 없었습니다.

대차 대조표

현금 런웨이 분석

과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.

안정적인 현금 활주로: SPRY 현재 무료 현금 흐름을 기준으로 3년 이상 충분한 현금 활주로를 보유하고 있습니다.

예측 현금 활주로: SPRY 42.5 1.5 42.5 % 매년.

ARS Pharmaceuticals 대차 대조표 상태

재무 상태 기준 확인 6/6

주요 정보

최근 재무 상태 업데이트

We're Interested To See How ARS Pharmaceuticals (NASDAQ:SPRY) Uses Its Cash Hoard To Grow

We're Not Very Worried About ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Rate

ARS Pharmaceuticals (NASDAQ:SPRY) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Situation

Recent updates

ARS Pharmaceuticals: Demand Curve Is Key Unknown

We're Interested To See How ARS Pharmaceuticals (NASDAQ:SPRY) Uses Its Cash Hoard To Grow

ARS Pharmaceuticals: A Decent Bet For Upside After Neffy Approval

ARS Pharmaceuticals, Inc. Launches Pre-Ordering Services for neffy to Help Patients Access the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis

ARS Pharmaceuticals, Inc. Announces Approval of EURneffy (adrenaline nasal spray) in the EU as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)

ARS Pharmaceuticals, Inc. Receives FDA Approval of Neffy® (Epinephrine Nasal Spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis

ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) dropped from Russell Small Cap Comp Value Index

ARS Pharmaceuticals, Inc. Announces EURneffy (Adrenaline Nasal Spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (Anaphylaxis)

ARS Pharmaceuticals On Track With Neffy Despite Regulatory Hurdles

First quarter 2024 earnings released: US$0.11 loss per share (vs US$0.16 loss in 1Q 2023)

ARS Pharmaceuticals, Inc. Submits Response for Neffy (Epinephrine Nasal Spray) Marketing Authorization Application to EMA's Chmp

ARS Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024

ARS Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024

Founder exercised options to buy US$1.6m worth of stock.

ARS Pharmaceuticals, Inc. Submits Response to FDA Complete Response Letter for Neffy® (Epinephrine Nasal Spray)

Consensus revenue estimates decrease by 19%, EPS upgraded

Full year 2023 earnings: EPS and revenues exceed analyst expectations

We're Not Very Worried About ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Rate

ARS Pharmaceuticals Announces neffy Meets Primary Endpoints and Shows Rapid Symptom Control in Phase 2 Urticaria Clinical Study

New minor risk - Profitability

Consensus revenue estimates decrease by 25%

Forecast to breakeven in 2026

ARS Pharmaceuticals, Inc. Announces Favorable Topline Results from Repeat Dosing Study of neffy (Epinephrine Nasal Spray) Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA’s Complete Response Letter

Consensus EPS estimates upgraded to US$0.64 loss

ARS Pharmaceuticals (NASDAQ:SPRY) Is In A Good Position To Deliver On Growth Plans

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: US$0.16 loss per share (vs US$0.25 loss in 3Q 2022)

Chief Legal Officer & Secretary recently bought US$320k worth of stock

Consensus revenue estimates decrease by 99%, EPS upgraded

ARS Pharmaceuticals, Inc. Announces FDA Issues Complete Response Letter for neffy(R) (epinephrine nasal spray) New Drug Application with Request for Additional Study

Co-Founder & Chief Science Officer recently sold US$26m worth of stock

Second quarter 2023 earnings released: US$0.18 loss per share (vs US$0.21 loss in 2Q 2022)

Consensus revenue estimates fall by 67%

First quarter 2023 earnings released: US$0.16 loss per share (vs US$0.24 loss in 1Q 2022)

Here's Why We're Not Too Worried About ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Situation

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Third quarter 2022 earnings released

ARS Pharmaceuticals, Inc. Appoints Brian T. Dorsey as Chief Operations Officer

Chief Financial Officer recently bought US$52k worth of stock

No independent directors

ARS Pharmaceuticals, Inc. Announces Presentation of Clinical Data Supporting Neffy® for the Treatment of Allergic Reactions (Type I) Including Anaphylaxis

ARS Pharmaceuticals, Inc. Announces Board Changes

재무 상태 분석

부채 대 자본 내역 및 분석

대차 대조표

현금 런웨이 분석

건강한 기업 발견하기